SS-31 (Elamipretide) vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | SS-31 (Elamipretide) | Substance P |
|---|---|---|
| Mechanism | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |